Traders Buy Large Volume of Call Options on ADMA Biologics (NASDAQ:ADMA)

Key Points

• Investors bought a surge of 22,398 call options on ADMA on March 26 (≈+848% vs. average) even as the stock tumbled 17.8% to $7.91 on outsized volume (~21.3M vs. 4.16M avg), indicating speculative bullish bets that could amplify intraday volatility.
• A short‑seller report by Culper Research sparked the selloff; ADMA disputed the claims but multiple law firms have opened shareholder investigations and short interest has risen to ~25.8M shares (≈11.3% of float), increasing legal and market‑risk for the stock.
• Signals are mixed from insiders and analysts: the COO sold 10,096 shares at about $15.63 while a director purchased 7,000 shares, and analyst ratings range from "hold" to "strong buy" with an average price target near $32.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 22,398 call options on the company. This is an increase of 848% compared to the typical daily volume of 2,362 call options.

Insider Activity

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm's stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steve Elms purchased 7,000 shares of the stock in a transaction dated Thursday, March 5th. The stock was purchased at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the purchase, the director directly owned 2,038,730 shares of the company's stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.50% of the company's stock.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Quadrant Capital Group LLC grew its position in ADMA Biologics by 3.9% in the second quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company's stock worth $303,000 after acquiring an additional 629 shares during the period. Lido Advisors LLC increased its stake in ADMA Biologics by 3.8% during the fourth quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company's stock worth $312,000 after acquiring an additional 629 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in ADMA Biologics by 11.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 634 shares during the period. Cim LLC lifted its stake in shares of ADMA Biologics by 0.7% in the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company's stock valued at $1,341,000 after purchasing an additional 665 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in shares of ADMA Biologics by 28.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 700 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Trading Down 17.8%

Shares of NASDAQ ADMA traded down $1.72 during trading on Thursday, hitting $7.91. 21,303,814 shares of the company were exchanged, compared to its average volume of 4,161,431. The company has a fifty day moving average price of $15.95 and a 200-day moving average price of $16.52. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. The firm has a market capitalization of $1.88 billion, a PE ratio of 13.31 and a beta of 0.51. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. During the same quarter in the prior year, the firm posted $0.46 earnings per share. ADMA Biologics's quarterly revenue was up 18.4% on a year-over-year basis. As a group, equities research analysts expect that ADMA Biologics will post 0.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Zacks Research upgraded ADMA Biologics from a "hold" rating to a "strong-buy" rating in a report on Monday, March 2nd. Cantor Fitzgerald reiterated a "neutral" rating on shares of ADMA Biologics in a research report on Thursday. Wall Street Zen raised shares of ADMA Biologics from a "hold" rating to a "buy" rating in a research note on Saturday, February 28th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, ADMA Biologics currently has an average rating of "Buy" and an average price target of $32.00.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Zacks added ADMA to its Rank #1 (Strong Buy) list on March 25, which can attract bargain‑hunters and momentum buyers. New Strong Buy Stocks for March 25th
• Positive Sentiment: Zacks also published a piece noting ADMA is deeply oversold and "ripe for a turnaround," highlighting technical oversold conditions and upward analyst estimate revisions that could support a rebound. Down 27% in 4 Weeks, Here's Why ADMA Looks Ripe for a Turnaround
• Positive Sentiment: Unusual options activity: investors bought ~22,398 call contracts on March 26 (≈+848% vs. average call volume), signaling speculative bullish interest or hedging ahead of potential news — this can amplify intraday volatility and short‑squeeze dynamics.
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a "neutral" rating on ADMA, which is unlikely to drive a directional move but frames investor expectations. Benzinga
• Negative Sentiment: A short‑seller report by Culper Research (Mar 24) triggered a sharp selloff and headlines about alleged issues; media coverage notes shares plunged on those allegations. This is the primary catalyst for today's weakness. Shares plunge on short‑seller allegations
• Negative Sentiment: ADMA publicly disputed the short‑seller report, calling parts misleading and saying the Board is reviewing assertions — but the rebuttal has not fully reversed the market reaction. ADMA Addresses Misleading Short‑Seller Report
• Negative Sentiment: Multiple law firms (Pomerantz, Frank R. Cruz, Ademi LLP) have launched shareholder investigations and securities‑fraud inquiries into ADMA, increasing legal and disclosure risk and pressuring the stock. Pomerantz investigation Frank R. Cruz investigation Ademi LLP investigation
• Negative Sentiment: Short interest surged in March (reports show ~25.8M shares short as of Mar 13, ~11.3% of float), indicating heavy bearish positioning that can both pressure the stock and fuel volatility if shorts cover.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.